Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Gets US Commercial Rights for Aquestive’s ALS Med
January 25, 2021
- Shipment Control Triggered for Bayer’s Stivarga on Overseas Delay
January 25, 2021
- Chugai, Taisho to Wind Up Edirol Sales Collaboration in April
January 25, 2021
- Maruho Seeks to Block Sales of Kenei’s Healmild, Claims Close Resemblance to Hirudoid
January 25, 2021
- Yescarta Approved in Japan as 2nd CAR-T Cell Therapy
January 22, 2021
- Kyowa Pharma Controlling Shipments of 4 Generics on Recalls, COVID-19
January 22, 2021
- Genmab Poised to Triple Japan Staff for Stand-Alone Biz, First Up Is ADC for Cervical Cancer
January 22, 2021
- Taisho Kicks Off Japan PIII for Lusefi in Pediatric Type 2 Diabetes
January 22, 2021
- Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
- Pfizer Launching Joint Research Aimed at Broadening Use of Medical Big Data
January 21, 2021
- Enhertu Approved for Breast Cancer in Europe: Daiichi Sankyo/AZ
January 21, 2021
- Will Cymbalta, E Keppra Face Generic Competition This Year? Vesicare, Aloxi Too?
January 20, 2021
- Sanofi Files Pompe Therapy Avalglucosidase Alfa in Japan
January 20, 2021
- Shionogi Files Xofluza for Continuous Manufacturing in Japan
January 20, 2021
- Rep Promotions via Virtual, Face-to-Face Meetings Dip in November: Intage
January 20, 2021
- Takeda Alumni Setting Up Biz Circle for Ex- and Current Employees
January 19, 2021
- Health Damages Tied to Kobayashi Kako Mix-Up Increase to 214
January 19, 2021
- Xarelto Now Available in OD Tablets, Japan-Specific Dosage Form
January 19, 2021
- Enhertu Gets FDA Nod for Gastric Cancer, 2nd Indication in US
January 19, 2021
- Mitsubishi Tanabe, Takeda Share Experimental Data to Speed Up Drug Discovery
January 19, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…